Premium
Disulfide Bond Reversible Strategy Enables GSH Responsive‐Transferrin Nanoparticles for Precise Chemotherapy
Author(s) -
Luo Yu,
Liu Xianping,
Liang Kaicheng,
Chen Qian,
Liu Tianzhi,
Yin Bo,
Chen Hangrong
Publication year - 2020
Publication title -
advanced therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
0ISSN - 2366-3987
DOI - 10.1002/adtp.202000064
Subject(s) - transferrin , transferrin receptor , glioma , doxorubicin , in vivo , drug delivery , blood–brain barrier , chemistry , glutathione , cancer research , biophysics , pharmacology , chemotherapy , biochemistry , medicine , biology , central nervous system , neuroscience , microbiology and biotechnology , organic chemistry , enzyme
Effective delivery of therapeutic agents into brain tissue for therapy of glioma remains a big challenge due to the presence of the blood‐brain barrier (BBB). Herein, a disulfide bond on–off–on triplet regulation strategy is developed to endow transferrin nanoparticles with high up to 18.1% drug‐loading efficiency. Such transferrin nanoparticles of around 70 nm, specifically, DOX@Tf m NPs, are synthesized via self‐assembly of modified transferrin with hydrophobic doxorubicin (DOX), displaying glutathione (GSH)‐responsive DOX release behavior in the tumor microenvironment. These DOX@Tf m NPs maintain the naturally targeted activity of transferrin, which can effectively cross the BBB and target the transferrin receptor overexpressed on the surface of glioma cells for precise chemotherapy of orthotopic glioma. In vivo results confirm that DOX@Tf m NPs can effectively target orthotopic glioma in living mice, achieving enhanced efficiency in inhibiting tumor growth and increasing survival rate without obvious side effects being observed. This study presents a new avenue to develop natural protein materials as promising smart drug delivery systems for clinical transformation.